Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function
NCT04933747
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
26
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Insufficiency
Interventions
DRUG:
Iberdomide
DRUG:
Iberdomide
Sponsor
Celgene